Forest had made $6 million upfront payment to Glenmark and also made an additional $3 million to support the next phase of work for the development of novel mPGES-1 inhibitors to treat chronic inflammatory conditions, including pain. Glenmark is expecting an additional payment to support the advancement of the programme.
Forest has an exclusive option to obtain license rights to the program upon the completion of pre-clinical trials. Under the terms of the agreement signed in FY 2012-13.
Glenmark’s current portfolio consists of 87 products authorized for distribution in the U.S. marketplace and 53, ANDA's pending approval with the U.S. FDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1785.00 |
Dr. Reddys Lab | 1355.00 |
Cipla | 1475.25 |
Lupin | 2185.50 |
Zydus Lifesciences | 1003.00 |
View more.. |